Hck-IN-1（Cat No.:I015534）is a selective inhibitor of hematopoietic cell kinase (Hck), a member of the Src family of tyrosine kinases, which plays a key role in regulating immune cell functions, proliferation, and survival. By targeting Hck, Hck-IN-1 disrupts signaling pathways involved in cancer cell growth and survival, particularly in hematological malignancies like chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). It has shown promise in preclinical studies for its potential to inhibit tumor progression and enhance the effectiveness of other cancer treatments, making it a valuable tool in cancer research.
| Catalog Number | I015534 |
| CAS Number | 1473404-51-1 |
| Molecular Formula | C₁₆H₁₁ClN₆O₃S |
| Purity | ≥95% |
| IUPAC Name | 4-[(3-chlorophenyl)diazenyl]-5-(4-nitrophenyl)-3-oxo-1H-pyrazole-2-carbothioamide |
| InChI | InChI=1S/C16H11ClN6O3S/c17-10-2-1-3-11(8-10)19-20-14-13(21-22(15(14)24)16(18)27)9-4-6-12(7-5-9)23(25)26/h1-8,21H,(H2,18,27) |
| InChIKey | LEQSBTDRMOZWRP-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC(=C1)Cl)N=NC2=C(NN(C2=O)C(=S)N)C3=CC=C(C=C3)[N+](=O)[O-] |
| Reference | [1]. Emert-Sedlak LA, et al. Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity. Chem Biol. 2013 Jan 24;20(1):82-91. |
